Filing Flows › Gilead Sciences (GILD) › Q4 2025
Gilead Sciences (GILD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Gilead Sciences (GILD) reported revenue of $7.9B for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +2% from the quarter before. Operating margin was 25.0%, net earnings $2.2B (27.5% of revenue).
Gilead Sciences, Q4 2025: revenue $7.9B (+5% year over year), operating margin 25.0%, net earnings $2.2B, operating cash flow $3.3B. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.9B | +2% | +5% |
| Operating profit | $2.0B | -40% | -19% |
| Net earnings | $2.2B | -28% | +22% |
| Operating cash flow | $3.3B | -19% | +12% |
| Free cash flow | $3.1B | — | +10% |
What changed
Revenue was $7.9B in Q4 2025, up 5% year over year and up 2% from the previous quarter. Biktarvy was the largest line at 50% of revenue.
Operating profit was $2.0B, a 25.0% margin (down 7.4 points year over year). Operating profit fell $0.47B even though revenue rose $0.36B versus a year earlier, so costs grew faster than sales. Total costs grew 16% against revenue growth of 5%. Net earnings were $2.2B, up 22% year over year. The effective tax rate was -5.1%.
Operating cash flow was $3.3B (up 12% year over year), 152% of net earnings. Non-cash charges added back $2.5B of depreciation and amortization and $0.23B of share-based compensation. Working capital and other items used $1.6B. After purchases of property, plant and equipment ($0.20B), free cash flow as the company reports it was $3.1B.
Questions
What was Gilead Sciences' revenue in the fourth quarter 2025?
Gilead Sciences (GILD) reported revenue of $7.9B for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +2% from the quarter before.
Was Gilead Sciences profitable in the fourth quarter 2025?
Operating profit was $2.0B (25.0% of revenue) and net earnings $2.2B.
Source: Gilead Sciences 10-K on SEC EDGAR.